Trial Refresh: A Case for an Adaptive Platform Trial for Pulmonary Exacerbations of Cystic Fibrosis
Cystic fibrosis is a genetic disease typically characterized by progressive lung damage and premature mortality.Pulmonary exacerbations, or flare-ups of the lung disease, often require hospitalization for intensive treatment.Approximately 25% of patients with cystic fibrosis do not recover their baseline lung function after pulmonary exacerbations.